122 related articles for article (PubMed ID: 8406342)
1. Subclinical hypothyroidism: a determinant of polycystic ovary syndrome.
Ghosh S; Kabir SN; Pakrashi A; Chatterjee S; Chakravarty B
Horm Res; 1993; 39(1-2):61-6. PubMed ID: 8406342
[TBL] [Abstract][Full Text] [Related]
2. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome.
Yucel A; Noyan V; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):81-6. PubMed ID: 16337726
[TBL] [Abstract][Full Text] [Related]
3. Hypoandrogenaemia is associated with subclinical hypothyroidism in men.
Kumar A; Chaturvedi PK; Mohanty BP
Int J Androl; 2007 Feb; 30(1):14-20. PubMed ID: 16879621
[TBL] [Abstract][Full Text] [Related]
4. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
5. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
van der Westhuizen S; van der Spuy ZM
Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
[TBL] [Abstract][Full Text] [Related]
6. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
[TBL] [Abstract][Full Text] [Related]
7. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
8. MANAGEMENT OF ENDOCRINE DISEASE: The impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: a systematic review and meta-analysis.
Pergialiotis V; Konstantopoulos P; Prodromidou A; Florou V; Papantoniou N; Perrea DN
Eur J Endocrinol; 2017 Mar; 176(3):R159-R166. PubMed ID: 28007842
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
[TBL] [Abstract][Full Text] [Related]
10. Peripheral steroid-gonadotropin interactions and diagnostic significance of double-stimulation tests with luteinizing hormone-releasing hormone in polycystic ovarian disease.
Moltz L; Römmler A; Schwartz U; Bidlingmaier F; Hammerstein J
Am J Obstet Gynecol; 1979 Aug; 134(7):813-8. PubMed ID: 380343
[No Abstract] [Full Text] [Related]
11. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
12. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
13. Macrophage migration inhibitory factor in obese and non obese women with polycystic ovary syndrome.
Mejia-Montilla J; Álvarez-Mon M; Reyna-Villasmil E; Torres-Cepeda D; Santos-Bolívar J; Reyna-Villasmil N; Suarez-Torres I; Bravo-Henríquez A
Endocrinol Nutr; 2015 Jan; 62(1):31-7. PubMed ID: 25458401
[TBL] [Abstract][Full Text] [Related]
14. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.
La Marca A; Orvieto R; Giulini S; Jasonni VM; Volpe A; De Leo V
Fertil Steril; 2004 Oct; 82(4):970-2. PubMed ID: 15482785
[TBL] [Abstract][Full Text] [Related]
15. Serum orexin-A (OXA) level decreases in polycystic ovarian syndrome.
Yilmaz E; Celik O; Celik N; Simsek Y; Celik E; Yildirim E
Gynecol Endocrinol; 2013 Apr; 29(4):388-90. PubMed ID: 23350701
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of polycystic ovarian disease.
James R; Givens MD
Acta Eur Fertil; 1979 Sep; 10(3):89-103. PubMed ID: 121017
[No Abstract] [Full Text] [Related]
17. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
18. [Endocrine effects of laser vaporization of the ovaries in women with polycystic ovary syndrome].
Rossmanith WG; Keckstein J; Spatzier K; Lauritzen C
Gynakol Rundsch; 1991; 31 Suppl 2():333-5. PubMed ID: 1790971
[No Abstract] [Full Text] [Related]
19. Effect of androgen excess on inappropriate gonadotropin secretion as found in the polycystic ovary syndrome.
Lobo RA; Goebelsmann U
Am J Obstet Gynecol; 1982 Feb; 142(4):394-401. PubMed ID: 6460446
[No Abstract] [Full Text] [Related]
20. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
Mehta RV; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
